AR052343A1 - Analogos de tetrahidroquinolina como agonistas muscarinicos - Google Patents

Analogos de tetrahidroquinolina como agonistas muscarinicos

Info

Publication number
AR052343A1
AR052343A1 ARP050105365A ARP050105365A AR052343A1 AR 052343 A1 AR052343 A1 AR 052343A1 AR P050105365 A ARP050105365 A AR P050105365A AR P050105365 A ARP050105365 A AR P050105365A AR 052343 A1 AR052343 A1 AR 052343A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
branched
straight
linear
alkyl
Prior art date
Application number
ARP050105365A
Other languages
English (en)
Inventor
Niels Skjaerbaek
Kristian Noruo Kogh
Bo Lennart Friberg
Bo-Ragnar Tolf
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of AR052343A1 publication Critical patent/AR052343A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de tetrahiroquinolina como agonistas de los receptores muscarínicos; composiciones que los comprenden; métodos para inhibir una actividad de un receptor muscarínico con dichos compuestos; métodos para tratar una condicion de enfermedad asociada con un receptor muscarínico usando dichos compuestos; y métodos para identificar un sujeto que es apropiado para tratar usando dichos compuestos. Reivindicacion 1: Un compuesto y sales e isomeros del mismo caracterizado porque responde a la formula (1) en donde: m es 0, 1 o 2; C3-4 es CH2-CR1R9 o CH=CR1 o C4 es CR1R9 y C3 está ausente; cada R1 y cada R9 se selecciona por separado entre el grupo que consiste en H, halogeno, hidroxi, alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, alquenilo C2-6 de cadena lineal o ramificada opcionalmente sustituido, alquinilo C2-6 de cadena lineal o ramificada opcionalmente sustituido, alquilideno C1-6 de cadena lineal o ramificada opcionalmente sustituido, alcoxi C1-6 de cadena lineal o ramificada opcionalmente sustituido, heteroalquilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, aminoalquilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, haloalquilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, alcoxicarbonilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, hidroxialcoxi C1-6 de cadena lineal o ramificada opcionalmente sustituido, hidroxialquilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, alquiltio C1-6 de cadena lineal o ramificada opcionalmente sustituido, O-alquenilo C2-6 de cadena lineal o ramificada opcionalmente sustituido, O-alquinilo C2-6 de cadena lineal o ramificada opcionalmente sustituido, alquenilalcoxi C3-6 de cadena lineal o ramificada opcionalmente sustituido, alquiloxiimino C1-6 de cadena lineal o ramificada opcionalmente sustituido, alquiloxiamino C1-6 de cadena lineal o ramificada opcionalmente sustituido, -O-CH2-arilo C5-6 opcionalmente sustituido, -C(O)NR10R11, -CR10R11R12, -OC(O)R10, -(O)(CH2)sNR11R12 de cadena lineal o ramificada opcionalmente sustituido, -(CH2)sNR11R12 de cadena lineal o ramificada opcionalmente sustituido, -OC(O)O(CH2)sCH3 de cadena lineal o ramificada opcionalmente sustituido, S-alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, S-alquenilo C2-6 de cadena lineal o ramificada opcionalmente sustituido y -S- alquinilo C2-6 de cadena lineal o ramificada opcionalmente sustituido, cada uno de los cuales que puede estar sustituido opcionalmente co uno o más sustituyentes Rx; cada R10 se selecciona por separado entre el grupo que consiste en H, alquilo C1-6 de cadena lineal o ramificada, alquenilo C2-6 de cadena lineal o ramificada, alquinilo C2-6 de cadena lineal o ramificada, heteroalquilo C2-6 de cadena lineal o ramificada, aminoalquilo C2-6 de cadena lineal o ramificada, haloalquilo C2-6 de cadena lineal o ramificada, alcoxicarbonilo C1-6 de cadena lineal o ramificada, hidroxialquilo C2-6 de cadena lineal o ramificada, cicloalquilo C3-8, -C(O)-C5-6 arilo sustituido con alquilo C1-3 o halo, arilo C5-6, heteroarilo C5-6, cicloalquilo C5-6, heterocicloalquilo C5-6, -C(O)NR11R12, -CR11R12R13, y - (CH2)sNR11R12 de cadena lineal o ramificada; cada s se selecciona por separado para que sea un entero entre 1 y 8; cada R11 y cada R12 se selecciona por separado entre el grupo que consiste en H, alquilo C1-6 de cadena lineal o ramificada, cicloalquilo C3-6 y heteroarilo C5-6, o cada uno de R11 y R12 forman juntos un cicloalquilo C3-8 o heterocicloalquilo C3-8; R13 se selecciona entre el grupo que cosiste en H, halogeno, alquilo C1-6 de cadena lineal o ramificada, formilo, y cicloalquilo C3-6; cada Rx se selecciona por separado entre el grupo que consiste en H, halogeno, hidroxi, alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituido, alcoxi C1-6 de cadena lineal o ramificada opcionalmente sustituido, cicloalquilo C3-8 opcionalmente sustituido, heterociclilo C3-8 opcionalmente sustituido, y alquilideno C1-6 de cadena lineal o ramificada opcionalmente sustituido; R2 y R3 se seleccionan por separado entre el grupo que consiste en H, alquilo C1-6 opcionalmente sustituido, O-alquilo C1-6 opcionalmente sustituido, halogeno, hidroxi o se seleccionan de tal manera que R2 y R3 están conectados de manera covalente para formar un sistema de anillo; cada R4 y cada R5 se seleccionan por separado entre el grupo que consiste en H, halogeno, hidroxi, alquilo C1-6 opcionalmente sustituido, O-alquilo C1-6 opcionalmente sustituido, aril-alquilo C1-6 opcionalmente sustituido, y arilheteroalquilo opcionalmente sustituido, L1 y L2 son bi-radicales que se seleccionan por separado entre el grupo que consiste en -C(R6)=C(R7), -C(R6)=N-, -N=C(R6)-, -S-, -NH- y -O-; donde solamente uno de L1 y L2 se puede seleccionar entre el grupo que consiste en -S-, -NH- y -O-; Y se selecciona entre el grupo que consiste en O, S, y H2; y X es un bi-radical que se selecciona entre el grupo que consiste en -C(R6)(R7)-C(R6)(R7)-, -C(R6)=C(R7)-, -O-C(R6)(R7)-, C(R6)(R7)-O-, -S-C(R6)(R7)-, - C(R6)(R7)-S, -N(RN)-C(R6)(R7)-, -C(R6)(R7)-N(RN)-, -C(R6)(R7)- C(R6)(R7)-C(R6)(R7)-, -O-C(R6)(R7)-C(R6)(R7)-, S-C(R6)(R7)-C(R6) (R7)-, N(RN)-C(R6)(R7)-C(R6)(R7)-, -C(R6)(R7)-C(R6)(R7)-O, -C(R6)(R7)-C(R6)(R7)-S, -C(R6)(R7)-C(R6)(R7)-N(RN)-, -C(R6)(R7) - C(R6)=C(R7)-, y C(R6)=C(R7)-C(R6)(R7), donde R6 y R7 se seleccionan por separado entre el grupo que consiste en H, halogeno, hidroxi, nitro, ciano, NRNRN, N(RN)-C(O)N(RN), alquilo C1-6 opcionalmente sustituido, alquenilo C2-6, alquinilo C2-6, O-alquilo C1-6 opcionalmente sustituido, O-arilo opcionalmente sustituido, O-alquenilo C2-6 opcionalmente sustituido, O-alquinilo C2-6 opcionalmente sustituido, donde RN que se selecciona entre el grupo que consiste en H, y alquilo C1-6 opcionalmente sustituido.
ARP050105365A 2004-12-21 2005-12-20 Analogos de tetrahidroquinolina como agonistas muscarinicos AR052343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/019,556 US7550459B2 (en) 2001-12-28 2004-12-21 Tetrahydroquinoline analogues as muscarinic agonists

Publications (1)

Publication Number Publication Date
AR052343A1 true AR052343A1 (es) 2007-03-14

Family

ID=36123554

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105365A AR052343A1 (es) 2004-12-21 2005-12-20 Analogos de tetrahidroquinolina como agonistas muscarinicos

Country Status (16)

Country Link
US (3) US7550459B2 (es)
EP (1) EP1828176A1 (es)
JP (1) JP5114208B2 (es)
KR (2) KR101380794B1 (es)
CN (2) CN101124222A (es)
AR (1) AR052343A1 (es)
AU (1) AU2005319426B2 (es)
BR (1) BRPI0517485A (es)
CA (1) CA2591766C (es)
IL (2) IL184065A (es)
MX (1) MX2007007588A (es)
NO (1) NO20073183L (es)
NZ (1) NZ555994A (es)
RU (1) RU2434865C2 (es)
TW (2) TWI433848B (es)
WO (1) WO2006068904A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
JP5398984B2 (ja) * 2005-06-24 2014-01-29 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2009106534A1 (en) * 2008-02-26 2009-09-03 H. Lundbeck A/S Novel heterocyclic carboxamides as m1 agonists
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PL2780015T3 (pl) 2011-11-18 2017-06-30 Heptares Therapeutics Limited Agonisty receptora muskarynowego M1
WO2014152144A1 (en) * 2013-03-15 2014-09-25 Acadia Pharmaceuticals Inc. Muscarinic agonists
CN103242230B (zh) * 2013-05-02 2015-02-18 陕西步长高新制药有限公司 一种喹啉酮衍生物及其制备方法
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
CN115073370A (zh) * 2021-03-10 2022-09-20 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324137A (en) * 1964-05-08 1967-06-06 Sterling Drug Inc N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes
US3365457A (en) * 1964-05-08 1968-01-23 Sterling Drug Inc N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives
US3364457A (en) * 1966-05-13 1968-01-16 Navy Usa Electrical adapter
JPS63290821A (ja) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
JP2886570B2 (ja) * 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
CA2050264A1 (en) 1990-08-30 1992-03-01 Raymond Baker Substituted pyrazine and its salts, compositions containing them and their use in medicine
US5149815A (en) * 1991-04-29 1992-09-22 American Home Products Corporation N-substituted-2-aminoquinolines
US5093333A (en) 1991-04-29 1992-03-03 American Home Products Corporation N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system
US5378698A (en) 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
JPH0673011A (ja) * 1992-07-02 1994-03-15 Sawai Seiyaku Kk カルボスチリル誘導体および抗アレルギー剤
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
DE4228095A1 (de) 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
TW448161B (en) * 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
JPH0881442A (ja) * 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
JP3118380B2 (ja) 1994-09-30 2000-12-18 三洋電機株式会社 光学レンズの焦点調節装置
US5510478A (en) 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5468875A (en) 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
EP0934932A4 (en) 1996-08-22 2002-06-26 Meiji Seika Kaisha CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
RU2230740C2 (ru) 1998-03-31 2004-06-20 Акадиа Фармасьютикалз, Инк. Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе
US6699880B1 (en) 1999-10-13 2004-03-02 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
EP1246817B1 (en) 1999-12-30 2004-06-23 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
ES2291293T3 (es) 2000-02-29 2008-03-01 Mitsubishi Pharma Corporation Nuevos derivados amida ciclicos.
BR0110420A (pt) 2000-04-28 2003-07-01 Acadia Pharm Inc Agonistas muscarìnicos
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US7307075B2 (en) 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
KR20050112116A (ko) 2003-03-28 2005-11-29 아카디아 파마슈티칼스 인코포레이티드 통증 관리를 위한 무스카린성 ｍ1 리셉터 작용제

Also Published As

Publication number Publication date
BRPI0517485A (pt) 2008-10-14
IL184065A (en) 2015-09-24
CN102796095A (zh) 2012-11-28
NZ555994A (en) 2010-09-30
RU2007127849A (ru) 2009-01-27
IL219920A0 (en) 2012-06-28
TW200634006A (en) 2006-10-01
JP2008524328A (ja) 2008-07-10
US9522906B2 (en) 2016-12-20
MX2007007588A (es) 2007-08-08
US8680115B2 (en) 2014-03-25
CA2591766C (en) 2014-09-09
CA2591766A1 (en) 2006-06-29
EP1828176A1 (en) 2007-09-05
NO20073183L (no) 2007-09-17
TWI433848B (zh) 2014-04-11
US7550459B2 (en) 2009-06-23
RU2434865C2 (ru) 2011-11-27
KR20070090003A (ko) 2007-09-04
AU2005319426B2 (en) 2011-10-13
US20090239903A1 (en) 2009-09-24
IL184065A0 (en) 2007-10-31
WO2006068904A1 (en) 2006-06-29
JP5114208B2 (ja) 2013-01-09
KR20130095846A (ko) 2013-08-28
AU2005319426A1 (en) 2006-06-29
CN102796095B (zh) 2015-09-09
US20140221364A1 (en) 2014-08-07
KR101380794B1 (ko) 2014-04-04
US20050209226A1 (en) 2005-09-22
IL219920A (en) 2016-04-21
TW201414731A (zh) 2014-04-16
AU2005319426A2 (en) 2006-06-29
CN101124222A (zh) 2008-02-13

Similar Documents

Publication Publication Date Title
AR052343A1 (es) Analogos de tetrahidroquinolina como agonistas muscarinicos
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
AR060401A1 (es) Derivados de cromen-2-ona
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
AR082004A1 (es) Compuestos de fusion de piridina
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR088449A1 (es) Benzilindazoles sustituidos
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR059516A1 (es) Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
AR054725A1 (es) Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
AR073136A1 (es) Compuestos de pirrol
GT200700036A (es) Compuestos fenil amido heterociclicos condensados
AR058404A1 (es) Derivados diamina como inhibidores de leucotrieno a4 hidrolasa
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
AR068466A1 (es) Cianoisoquinolina
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
NI201000049A (es) Método para producir 2&#39;-desoxi-5-azacitidina (decitabina)
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
ES2603931T3 (es) Compuestos de triazolo
AR056194A1 (es) Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular

Legal Events

Date Code Title Description
FB Suspension of granting procedure